Restricted Research - Award List, Note/Discussion Page

Fiscal Year: 2018

1675  University of Houston  (75493)

Principal Investigator: Ruiwen Zhang

Total Amount of Contract, Award, or Gift (Annual before 2011): $ 1,193,203

Exceeds $250,000 (Is it flagged?): Yes

Start and End Dates: 9/1/17 - 2/28/19

Restricted Research: YES

Academic Discipline: PHARMACOLOGICAL & PHARMACEUTIC

Department, Center, School, or Institute: DEAN, PHARMACY

Title of Contract, Award, or Gift: NOVEL SMALL MOLECULE MDM2 INHIBITORS FOR PANCREATIC CANCER THERAPY

Name of Granting or Contracting Agency/Entity: National Cancer Institute
CFDA Link: HHS
93.859

Program Title: CHANGE OF GRANTEE ORGANIZATION (TYPE 7 PARENT)
CFDA Linked: Biomedical Research and Research Training

Note:

1.1.1 - The long-term goal of this project is to develop novel targeted therapy for human pancreatic cancer (pancreatic ductal adenocarcinoma, PDA).

Discussion: No discussion notes

 

Close Window